Effect of non-invasive preimplantation genetic testing for aneuploidies (ni-PGT) on cumulative ongoing pregnancy in infertile women of advanced maternal age: a multicentre, open-label, randomised controlled trial protocol

03 Jun 20265 min read0 viewsJournal Feed

GIST (Key Takeaways)

Introduction Embryo aneuploidy increases substantially with maternal age, contributing to implantation failure and miscarriage. Conventional morphological assessment cannot determine euploidy.
Non-invasive preimplantation genetic testing (ni-PGT) evaluates cell-free DNA in spent embryo culture medium, potentially improving embryo selection without trophectoderm biopsy. Robust evidence of clinical benefit in women aged 35 - 42 years remains limited.
Methods and analysis This is a multicentre, open-label, parallel-group randomised controlled trial conducted in three centres in China. Infertile women aged 35 - 42 years undergoing their first intracytoplasmic sperm injection cycle and having ≥2 good-quality days 5 - 6 blastocysts (Gardner grade ≥4BC,defined as an expansion grade of at least 4, with an inner cell mass grade of B or better and a trophectoderm grade of C or better) will be randomised 1:1 to ni-PGT-guided embryo selection or conventional morphology-based selection.
Randomisation will be stratified by study centre using variable permuted block sizes of 4 and 6 and implemented through a unified centralised randomisation system.

Clinical Editorial

Summary

BMJ Open published a clinical update in Research Highlights on 03 Jun 2026.

The item focuses on Effect of non-invasive preimplantation genetic testing for aneuploidies (ni-PGT) on cumulative ongoing pregnancy in infertile women of advanced maternal age: a multicentre, open-label, randomised controlled trial protocol.

Review the original article for the full source wording and details.